CG Invites Co

CG Invites Co Goodwill

The Goodwill of CG Invites Co (083790.KQ) as of Nov 18, 2026 is 7.39 B KRW. In the previous year, Goodwill was 3.23 B KRW — a change of 128.53% (higher).

Goodwill

7.39 BKRW

YoY

128.53%

Last updated:

Goodwill of CG Invites Co is 2025 7.39 B KRW. Goodwill of CG Invites Co was 2024 3.23 B KRW. It decreases by 128.53% higher compared to the previous year.

The CG Invites Co Goodwill history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Goodwill
Date
Goodwill
Jan 1, 2018
0.00 KRW
Jan 1, 2019
5.73 B KRW
Jan 1, 2020
2.03 B KRW
Jan 1, 2021
2.03 B KRW
Jan 1, 2022
2.03 B KRW
Jan 1, 2023
0.00 KRW
Jan 1, 2024
3.23 B KRW
Jan 1, 2025
7.39 B KRW
The CG Invites Co Goodwill history
YEARGoodwillYoY
7.39 BKRW+128.53%
3.23 BKRW—
0.00KRW-100.00%
2.03 BKRW0.00%
2.03 BKRW0.00%
2.03 BKRW-64.66%
5.73 BKRW—
0.00KRW-100.00%
2.33 BKRW-53.22%
4.99 BKRW-0.15%
4.99 BKRW+114.09%
2.33 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

CG Invites Co Stock analysis

What does CG Invites Co do? CrystalGenomics, Inc. generates revenue through its Finished Pharmaceuticals Manufacturing segment, which produces and sells finished pharmaceuticals. The Pharmaceutical R&D Division provides clinical trial analysis and technical services while also selling new drugs. The company also operates in the real estate leasing business under the segment structure. The Others segment manufactures and sells hot fats and other household items. Revenue streams are derived from pharmaceutical manufacturing, R&D services, real estate leasing, and household product sales. The primary buyers for finished pharmaceuticals include healthcare providers and distributors. Clinical trial analysis and new drug sales target pharmaceutical companies and research institutions. Real estate leasing serves commercial tenants, while hot fats and household items are sold to retail consumers. The company's segments collectively serve diverse markets across healthcare, real estate, and consumer goods. CrystalGenomics, Inc. focuses on therapeutic discovery and development, with its R&D Division driving innovation in new drug sales. The Finished Pharmaceuticals Manufacturing segment ensures steady supply of established products. Real estate leasing and household item sales provide additional revenue streams. The company's business model integrates pharmaceutical production, research, and non-pharmaceutical ventures. CG Invites Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about CG Invites Co stock

Goodwill of CG Invites Co is 7.39 B KRW in 2025.

Goodwill of CG Invites Co changed from 3.23 B KRW to 7.39 B KRW, representing a 128.53% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Goodwill CG Invites Co since 2006 – with annual values, charts, and detailed analysis.

Goodwill is the premium paid above fair market value in an acquisition. It represents intangible value such as brand recognition, customer relationships, and intellectual property.

Goodwill's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Goodwill's CG Invites Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — CG Invites Co

All Key Metrics — CG Invites Co